MWM
CRSP icon

MBE Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

MBE Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-250
Closed -$10K – 140
2020
Q1 		$10K Buy
+250
New +$12.9K 0.01% 280

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

MBE Wealth Management's CRSP Position: Q2 2020 in Review

MBE Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q2 2020, closing a stake of 250 shares — an estimated $10K sold.

MBE Wealth Management first reported a position in CRSP in Q1 2020 and held it in 1 quarter. The position peaked at $10K in Q1 2020. 276 funds tracked by Wall St. Rank hold CRSP as of Q2 2020.

  • MBE Wealth Management reported no remaining CRISPR Therapeutics position as of Q2 2020 after selling out during the quarter.
  • MBE Wealth Management sold 250 CRISPR Therapeutics shares in Q2 2020, an estimated $10K.
  • MBE Wealth Management first reported a position in CRISPR Therapeutics in Q1 2020 and held it in 1 quarter.
  • MBE Wealth Management's CRISPR Therapeutics position peaked at $10K in Q1 2020.
  • 276 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2020.

Based on MBE Wealth Management's 13F filing for Q2 2020, filed 14 Aug 2020.